Evolution of raltegravir resistance during therapy

Objectives We investigated the prevalence of raltegravir resistance-associated mutations at baseline and their evolution during raltegravir therapy in patients infected with different HIV-1 subtypes. Methods At pre-treatment screening, the integrase gene from plasma samples from patients infected wi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2009-07, Vol.64 (1), p.25-32
Main Authors: Sichtig, Nadine, Sierra, Saleta, Kaiser, Rolf, Däumer, Martin, Reuter, Stefan, Schülter, Eugen, Altmann, Andre, Fätkenheuer, Gerd, Dittmer, Ulf, Pfister, Herbert, Esser, Stefan
Format: Article
Language:English
Subjects:
Amino Acid Substitution - genetics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral drugs
antiviral therapy
Biological and medical sciences
DNA Mutational Analysis
Drug resistance
Drug Resistance, Viral
Genotype & phenotype
HIV
HIV Infections - drug therapy
HIV Infections - virology
HIV Integrase - genetics
HIV-1
HIV-1 - drug effects
HIV-1 - genetics
HIV-1 - isolation & purification
Human immunodeficiency virus
Human immunodeficiency virus 1
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
integrase inhibitors
Medical sciences
Molecular Sequence Data
Mutation
Mutation, Missense
non-B subtypes
Pharmacology. Drug treatments
Pyrrolidinones - pharmacology
Pyrrolidinones - therapeutic use
Raltegravir Potassium
Sequence Analysis, DNA
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives We investigated the prevalence of raltegravir resistance-associated mutations at baseline and their evolution during raltegravir therapy in patients infected with different HIV-1 subtypes. Methods At pre-treatment screening, the integrase gene from plasma samples from patients infected with subtype B and non-B viruses was analysed. Raltegravir resistance evolution was further evaluated in 10 heavily pre-treated patients. Results Two hundred and nine plasma samples from 94 subtype B and 115 non-B patients were sequenced. No signature/primary raltegravir resistance mutations were detected at baseline. The secondary mutations L74M, T97A, V151I and G163R were observed with a frequency of
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkp153